HEPA Profile
Hepion Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the development of innovative therapies for chronic liver diseases. Based in Edison, New Jersey, the company focuses on advancing treatments that address various liver conditions through its proprietary drug candidates. Hepion is at the forefront of developing Rencofilstat, a cyclophilin inhibitor designed to target multiple pathological pathways involved in liver disease progression. Rencofilstat has completed Phase 2a clinical trials, demonstrating its potential in treating non-alcoholic steatohepatitis (NASH), a severe form of liver inflammation and damage. The drug is also in ongoing clinical-phase development for NASH, with additional nonclinical studies exploring its efficacy in reducing liver fibrosis and tumor burden associated with hepatocellular carcinoma in experimental NASH models.
Beyond its primary focus on liver diseases, Hepion Pharmaceuticals is investigating Rencofilstat’s antiviral properties. The drug has shown promising activity against hepatitis B, C, and D viruses, suggesting it may offer therapeutic benefits for patients with these chronic viral infections. This broad antiviral activity further positions Rencofilstat as a versatile treatment option with the potential to address multiple aspects of liver-related conditions.
Hepion Pharmaceuticals, formerly known as ContraVir Pharmaceuticals, Inc., rebranded in July 2019 to better reflect its expanded focus on liver disease therapies. The company, incorporated in 2013, has since leveraged its research and development capabilities to advance its pipeline of drug candidates and pursue innovative treatment solutions for chronic liver conditions.
With a commitment to improving patient outcomes and advancing liver disease treatments, Hepion Pharmaceuticals continues to build on its research and clinical development efforts. The company's strategic focus on Rencofilstat and its ongoing studies underscore its dedication to addressing significant unmet medical needs in the field of hepatology and antiviral therapeutics.
|
